In breast cancer, CD44 increased cell invasion and activated MAPK signaling pathway through promotion of the expression of NHE1, and the repression of NHE1 by PPARγ ligands sensitized tumor cells to paclitaxel [18, 19]. This evidence concerns the gene SLC9A1 and breast carcinoma.